These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 8165652)

  • 1. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis.
    Collen D; Lu HR; Stassen JM; Vreys I; Yasuda T; Bunting S; Gold HK
    Thromb Haemost; 1994 Jan; 71(1):95-102. PubMed ID: 8165652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model.
    Imura Y; Stassen JM; Bunting S; Stockmans F; Collen D
    Blood; 1992 Sep; 80(5):1247-53. PubMed ID: 1515641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
    Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D
    Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation.
    Yasuda T; Gold HK; Kohmura C; Guerrero L; Yaoita H; Fallon JT; Bunting S; Collen D
    Arterioscler Thromb; 1993 May; 13(5):738-47. PubMed ID: 8485125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective alpha IIb beta 3 receptor blockage with peptide TP9201 prevents platelet uptake on Dacron vascular grafts without significant effect on bleeding time.
    Mazur C; Tschopp JF; Faliakou EC; Gould KE; Diehl JT; Pierschbacher MD; Connolly RJ
    J Lab Clin Med; 1994 Oct; 124(4):589-99. PubMed ID: 7523555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs.
    Lu HR; Gold HK; Wu Z; Yasuda T; Pauwels P; Rapold HJ; Napier M; Bunting S; Collen D
    Thromb Haemost; 1992 Jun; 67(6):686-91. PubMed ID: 1509410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis.
    Rote WE; Davis JH; Mousa SA; Reilly TM; Lucchesi BR
    J Cardiovasc Pharmacol; 1994 Apr; 23(4):681-9. PubMed ID: 7516023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous antiplatelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP 728 in anesthetized dogs.
    Mousa SA; Flint S; Lorelli W; Hassell S; Bozarth J; De Grado W; Reilly TM
    Thromb Res; 1994 Oct; 76(2):109-19. PubMed ID: 7863463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
    Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.
    Uemura T; Kawasaki T; Taniguchi M; Moritani Y; Hayashi K; Saito T; Takasaki J; Uchida W; Miyata K
    Br J Pharmacol; 2006 May; 148(1):61-9. PubMed ID: 16520742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits.
    Roussa VD; Stathopoulou EM; Papamichael ND; Englezopoulos CV; Rousouli KI; Trypou P; Moussis V; Tellis CC; Katsouras CS; Tsikaris V; Tselepis AD; Michalis LK
    Platelets; 2011; 22(5):361-70. PubMed ID: 21158497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
    Huang J; Rebello SS; Faul JD; Lucchesi BR
    Pharmacology; 1999 May; 58(5):252-64. PubMed ID: 10087466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
    Cook NS; Bruttger O; Pally C; Hagenbach A
    Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal anti-platelet glycoprotein IIb/IIIa antibody in a baboon model.
    Kotzé HF; Badenhorst PN; Lamprecht S; Meiring M; Van Wyk V; Nuyts K; Stassen JM; Vermylen J; Deckmyn H
    Thromb Haemost; 1995 Aug; 74(2):751-7. PubMed ID: 8585017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog.
    Rebello SS; Driscoll EM; Lucchesi BR
    Stroke; 1997 Sep; 28(9):1789-96. PubMed ID: 9303027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.
    Sabatine MS; Tu TM; Jang IK
    J Thromb Thrombolysis; 2000 Oct; 10(2):189-96. PubMed ID: 11005941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of TAK-029, a novel GPIIb/IIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeys.
    Kawamura M; Tsuji N; Moriya N; Terashita Z
    Thromb Res; 1997 May; 86(4):275-85. PubMed ID: 9187016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.